Experts Suggest Targeting How To Treat Migraine.
The holidays can call into doubt the estimated 30 million migraine sufferers in the United States as they look over to deal with crowds, fraternize delays, stress and other potential headache triggers. Even if you don't get the debilitating headaches, there's a high-mindedness chance you have loved ones who do. Nearly one in four US households includes someone afflicted with migraines, according to the Migraine Research Foundation. There are a sum of ways to make do with migraines during the holidays, said David Yeomans, director of pain research at the Stanford University School of Medicine Dec 2013.
Along with expert and trying to avoid your migraine triggers, you deprivation to be prepared to deal with a headache. Light sensitivity, changes in sleep patterns, and certain foods and smells - all base migraine triggers - might be harder to avoid during the holiday season. "When you've got kinsmen over or are at a loved one's home, it can be tricky to adjust your normal pattern or routine," Yeomans said in a news release.
Showing posts with label hormone. Show all posts
Showing posts with label hormone. Show all posts
Wednesday 20 November 2019
Monday 22 May 2017
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy
Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a conclusion that seems to token the prevailing wisdom that any form of hormone replacement cure raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone group therapy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone treatment is actually protective" in women who have a low risk for developing heart tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another glance at text from the Women's Health Initiative (WHI) study, a nationalistic trial that has focused on ways to prevent breast and colorectal cancer, as well as guts disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, unequal studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were part of the trial run - women who had had hysterectomies and took estrogen unassisted as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The confederation therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no ex history of benign heart of hearts disease had a 43 percent reduction breast cancer risk on estrogen; women with no kinsfolk history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without foregoing hormone use had a 32 percent reduced risk.
In a conclusion that seems to token the prevailing wisdom that any form of hormone replacement cure raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone group therapy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone treatment is actually protective" in women who have a low risk for developing heart tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another glance at text from the Women's Health Initiative (WHI) study, a nationalistic trial that has focused on ways to prevent breast and colorectal cancer, as well as guts disease and fracture risk, in postmenopausal women.
The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by appearance experts, unequal studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.
Two groups were part of the trial run - women who had had hysterectomies and took estrogen unassisted as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The confederation therapy trial was halted in 2002 after it became clear those women were at increased peril for heart disease and breast cancer.
In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no ex history of benign heart of hearts disease had a 43 percent reduction breast cancer risk on estrogen; women with no kinsfolk history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without foregoing hormone use had a 32 percent reduced risk.
Wednesday 8 March 2017
An Effect Of Hormone Therapy On Breast Cancer
An Effect Of Hormone Therapy On Breast Cancer.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Although several overweight studies in latest years have linked the use of hormone therapy after menopause with an increased danger of breast cancer, the authors of a new analysis claim the evidence is too limited to confirm the connection. Dr Samuel Shapiro, of the University of Cape Town Medical School in South Africa, and his colleagues took another air at three eminently studies that investigated hormone therapy and its credible health risks - the Collaborative Reanalysis, the Women's Health Initiative (WHI) and the Million Women Study. Together, the results of these studies found overall an increased jeopardize of breast cancer centre of women who used the combination form of hormone therapy with both estrogen and progesterone.
Women who have had a hysterectomy and use estrogen-only group therapy also have an increased risk, two of the studies found. The WHI, however, found that estrogen-only remedy may not increase breast cancer risk and may actually decrease it, although that has not been confirmed in other research. After the WHI scrutinize was published in July 2002, women dropped hormone cure in droves.
Many experts pointed to that decline in hormone therapy use as the reason breast cancer rates were declining. Not so, Shapiro said: "The declivity in breast cancer extent started three years before the fall in HRT use commenced, lasted for only one year after the HRT dab commenced, and then stopped". For instance between 2002 and 2003, when large numbers of women were still using hormone therapy, the numeral of new breast cancer cases fell by nearly 7 percent.
In taking a bearing at the three studies again, Shapiro and his team reviewed whether the evidence satisfied criteria superior to researchers, such as the strength of an association, taking into account other factors that could influence risk. Their conclusion: The fact is not strong enough to say definitively that hormone therapy causes breast cancer. The go into is published in the current issue of the Journal of Family Planning and Reproductive Health Care.
Subscribe to:
Posts (Atom)